Thian Kheoh, PhD

Thian Kheoh, PhD, joined Elicio in August 2023 as Senior Vice President, Biometrics. Thian has over 33 years of drug development and clinical trial experience in large pharmaceutical as well as small biotechnology companies. His work included clinical trials in small molecules and biologics, exploring applications of statistical methodologies in preclinical and clinical studies, integrating novel statistical principles to trial design, and strategic planning to bring effective drugs to cancer patients.

Prior to joining Elicio, Thian was the Vice President, Biometrics at Mirati Therapeutics where he established and built the department. He led the Biometrics team in the FDA submission and approval of KRAZATI® for KRAS G12C NSCLC patients, under Breakthrough Therapy and Accelerated Approval designation. Prior to Mirati, he held roles of increasing responsibility at Tocagen, Janssen, Cougar Biotechnology (acquired by J&J for $1Billion), Biogen-IDEC, TAP, and Warner Lambert-Parke Davis. Thian played an integral role in a number of successful global regulatory submissions and approvals of products that include DARZALEX®, ERLEADA®, OMNICEF®, SYLVANT®, VELCADE®, YONDELIS®, ZYTIGA®, and the label expansion of RITUXAN®.

Before joining the biopharmaceutical industry, he was an assistant professor at the University of Central Florida conducting research and lecture in Statistics. Thian earned his PhD in Statistics from the University of Western Ontario, Canada.